Key statistics
On Friday, ARS Pharmaceuticals Inc (SPRY:NMQ) closed at 8.85, 32.88% above the 52 week low of 6.66 set on Nov 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.91 |
|---|---|
| High | 9.18 |
| Low | 8.61 |
| Bid | 8.85 |
| Offer | 9.25 |
| Previous close | 8.81 |
| Average volume | 1.23m |
|---|---|
| Shares outstanding | 98.85m |
| Free float | 82.22m |
| P/E (TTM) | -- |
| Market cap | 874.81m USD |
| EPS (TTM) | -0.9012 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
- EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
- California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
- neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
- ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
- ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
- UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
- ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
- ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
More ▼
